Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Roquefort Therapeutics plc is a biotechnology research company focused on developing innovative drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator implicated in cancer progression. Incorporated in 2020 and headquartered in London, United Kingdom, the firm operates within the healthcare sector, specifically the biotechnology industry, with a lean team of seven full-time employees led by CEO Stephen Paul West. Its primary mission centers on advancing research and experimental development in biotechnology, as classified under SIC code 72110, to create therapeutic solutions for oncology. Roquefort Therapeutics plc plays a niche role in the financial markets by representing early-stage biopharma innovation, where small-cap biotech firms like itself contribute to the pipeline of potential cancer treatments amid ongoing clinical advancements, such as extensions to licensing agreements for key assets. Previously known as Roquefort Investments PLC until late 2021, the company maintains an active status and continues to file regular accounts and confirmation statements with UK authorities. This positions it as a speculative interest in the broader ecosystem of medical research and drug discovery.
£0.10
+£0.00 (+0.00%)
EOD Jul 3, 2026
Negative free cash flow of -£646K. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£3M
▼ -246.0% YoY
Op. Margin
—
ROIC
-16.85%
▼ -0.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£646K
▲ +17.6% YoY
Op. Cash Flow (TTM)
-£646K
▲ +17.6% YoY
Net Debt
-£78K
Net Cash Position
Cash & Equiv.
£78K
Continue Research
Roquefort Therapeutics (ROQ.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Roquefort Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Roquefort Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -16.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ROQ.XLON's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.